These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11309548)

  • 1. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation.
    Kovarik JM; Nashan B; Neuhaus P; Clavien PA; Gerbeau C; Hall ML; Korn A
    Clin Pharmacol Ther; 2001 Apr; 69(4):201-9. PubMed ID: 11309548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group.
    Kovarik JM; Kahan BD; Rajagopalan PR; Bennett W; Mulloy LL; Gerbeau C; Hall ML
    Transplantation; 1999 Nov; 68(9):1288-94. PubMed ID: 10573065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm.
    Kovarik JM; Gridelli BG; Martin S; Rodeck B; Melter M; Dunn SP; Merion RM; Tzakis AG; Alonso E; Bucuvalas J; Sharp H; Gerbeau C; Chodoff L; Korn A; Hall M
    Pediatr Transplant; 2002 Jun; 6(3):224-30. PubMed ID: 12100507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition and immunodynamics of basiliximab in liver allograft recipients.
    Kovarik J; Breidenbach T; Gerbeau C; Korn A; Schmidt AG; Nashan B
    Clin Pharmacol Ther; 1998 Jul; 64(1):66-72. PubMed ID: 9695721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for basiliximab exposure-response relationships in renal allotransplantation.
    Kovarik JM; Moore R; Wolf P; Abendroth D; Landsberg D; Soulillou JP; Gerbeau C; Schmidt AG
    Clin Transplant; 1999 Feb; 13(1 Pt 1):32-8. PubMed ID: 10081632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients.
    Kovarik JM; Pescovitz MD; Sollinger HW; Kaplan B; Legendre C; Salmela K; Book BK; Gerbeau C; Girault D; Somberg K;
    Clin Transplant; 2001 Apr; 15(2):123-30. PubMed ID: 11264639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations.
    Kovarik JM; Offner G; Broyer M; Niaudet P; Loirat C; Mentser M; Lemire J; Crocker JF; Cochat P; Clark G; Gerbeau C; Chodoff L; Korn A; Hall M
    Transplantation; 2002 Oct; 74(7):966-71. PubMed ID: 12394838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
    Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
    Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.
    Neuhaus P; Clavien PA; Kittur D; Salizzoni M; Rimola A; Abeywickrama K; Ortmann E; Chodoff L; Hall M; Korn A; Nashan B;
    Liver Transpl; 2002 Feb; 8(2):132-42. PubMed ID: 11862589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts.
    Kovarik J; Wolf P; Cisterne JM; Mourad G; Lebranchu Y; Lang P; Bourbigot B; Cantarovich D; Girault D; Gerbeau C; Schmidt AG; Soulillou JP
    Transplantation; 1997 Dec; 64(12):1701-5. PubMed ID: 9422405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation.
    Mehra MR; Zucker MJ; Wagoner L; Michler R; Boehmer J; Kovarik J; Vasquez A
    J Heart Lung Transplant; 2005 Sep; 24(9):1297-304. PubMed ID: 16143248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM; Keating GM
    Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of intragraft IL-2 receptor-alpha by basiliximab is insufficient to prevent activation of liver graft infiltrating cells.
    Kwekkeboom J; Warlé MC; Rietveld J; Segeren KC; Tilanus HW; Metselaar HJ
    Transpl Immunol; 2003; 11(1):1-5. PubMed ID: 12727469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basiliximab-chimeric anti-IL2-R monoclonal antibody in pediatric liver transplantation: comparative study.
    Gibelli NE; Pinho-Apezzato ML; Miyatani HT; Maksoud-Filho JG; Silva MM; Ayoub AA; Santos MM; Velhote MC; Tannuri U; Maksoud JG
    Transplant Proc; 2004 May; 36(4):956-7. PubMed ID: 15194332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation.
    Keown P; Balshaw R; Khorasheh S; Chong M; Marra C; Kalo Z; Korn A
    BioDrugs; 2003; 17(4):271-9. PubMed ID: 12899644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication.
    Höcker B; Kovarik JM; Daniel V; Opelz G; Fehrenbach H; Holder M; Hoppe B; Hoyer P; Jungraithmayr TC; Köpf-Shakib S; Laube GF; Müller-Wiefel DE; Offner G; Plank C; Schröder M; Weber LT; Zimmerhackl LB; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1234-40. PubMed ID: 19005405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen.
    Thibault G; Paintaud G; Legendre C; Merville P; Coulon M; Chasseuil E; Ternant D; Rostaing L; Durrbach A; Di Giambattista F; Büchler M; Lebranchu Y
    Transpl Int; 2016 Feb; 29(2):184-95. PubMed ID: 26369526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.